Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

OBJECTIVES: Baloxavir marboxil (formerly S-033188) is a first-in-class, orally available, cap-dependent endonuclease inhibitor licensed in Japan and the USA for the treatment of influenza virus infection. We evaluated the efficacy of delayed oral treatment with baloxavir marboxil in combination with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Antimicrob Chemother
Autores principales: Fukao, Keita, Noshi, Takeshi, Yamamoto, Atsuko, Kitano, Mitsutaka, Ando, Yoshinori, Noda, Takahiro, Baba, Kaoru, Matsumoto, Kazumi, Higuchi, Naoko, Ikeda, Minoru, Shishido, Takao, Naito, Akira
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6376846/
https://ncbi.nlm.nih.gov/pubmed/30476172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky462
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares